Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2009-02-05
2010-10-05
Helms, Larry R. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S130100
Reexamination Certificate
active
07807792
ABSTRACT:
A tumor antigen that comprises, as an active ingredient, a product of the Wilms' tumor suppressor gene WT1 or a peptide composed of 7-30 contiguous amino acids containing an anchor amino acid for binding to major histocompatibility complex (MHC) class I in said amino acid sequence, and a vaccine comprising said antigen.
REFERENCES:
patent: 5622835 (1997-04-01), Herlyn et al.
patent: 5726288 (1998-03-01), Call et al.
patent: 5731160 (1998-03-01), Melief et al.
patent: 7030212 (2006-04-01), Sugiyama et al.
patent: 7342092 (2008-03-01), Sugiyama et al.
patent: 7378384 (2008-05-01), Sugiyama et al.
patent: 7390871 (2008-06-01), Sugiyama et al.
patent: 7420034 (2008-09-01), Sugiyama et al.
patent: 7517950 (2009-04-01), Sugiyama et al.
patent: 2004/0097703 (2004-05-01), Sugiyama et al.
patent: 2004/0247609 (2004-12-01), Sugiyama et al.
patent: 2005/0002951 (2005-01-01), Sugiyama et al.
patent: 2006/0093615 (2006-05-01), Sugiyama et al.
patent: 2006/0217297 (2006-09-01), Sugiyama et al.
patent: 2007/0128207 (2007-06-01), Sugiyama et al.
patent: 2008/0070835 (2008-03-01), Sugiyama
patent: 2008/0152631 (2008-06-01), Sugiyama
patent: 2009/0099090 (2009-04-01), Sugiyama et al.
patent: 2009/0143291 (2009-06-01), Sugiyama et al.
patent: 1 103 564 (2001-05-01), None
patent: 9823897.5 (1998-11-01), None
patent: 218093/1988 (1998-07-01), None
patent: 2002-525099 (2002-08-01), None
patent: WO 97/26328 (1997-07-01), None
patent: WO 00/18795 (2000-04-01), None
patent: WO 00/26249 (2000-05-01), None
Alan J. Buckler, et al., “Isolation, Characterization, and Expression of the Murine Wilms' Tumor Gene (WT1)During Kidney Development”, Molecular and Cellular Biology, American Society for Microbiology, vol. 11, No. 3, Mar. 1991, XP002922234, pp. 1707-1712.
Drew M. Pardoll, “New Strategies for Enhancing the Immunogenicity of Tumors”, Current Opinion in Immunology, vol. 5, 1993, XP002922233, pp. 719-725.
Hans-Georg Rammensee, et al., “MHC Ligands and Peptide Motifs: First Listing”, Immunogenetics, vol. 41, 1995, XP002922231, pp. 178-228.
M. Yasukawa, et al., “HLA Class I-Restricted Lysis of Leukemia Cells by a CD8 Cytotoxic T-Lymphocyte Clone Directed Against WT1 Peptide”, Blood, vol. 92, No. 10SUPP01PT1/2, Nov. 15, 1998, XP001053538, p. 616A.
Yoshihiro Oka, et al., “Human Cytotoxic T-Lymphocyte Responses Specific for Peptides of the Wild-Type Wilms' Tumor Gene (WT1) Product”, Immunogenetics, vol. 51, No. 2, Feb. 1, 2000, XP000884935, pp. 99-107.
Yoshihiro Oka, et al., “Induction of WT1 (Wilms' Tumor Gene)-Specific Cytotoxic T Lymphocytes by WT1 Peptide vaccine and the Resultant Cancer Regression”, Proceedings of the National Academy of Sciences of USA, vol. 101, No. 38, Sep. 21, 2004, XP003013276, pp. 13885-13890.
Prem Mohini Sharma, et al., “Molecular Cloning of Rat Wilms' Tumor Complementary DNA and a Study of Messenger RNA Expression in the Urogenital System and the Brain1” Cancer Research, vol. 52, Nov. 15, 1992, pp. 6407-6412.
Em Algar, et al., “A WT1 Antisense Oligonucleotide Inhibits Proliferation and Induces Apoptosis in Myeloid Leukaemia Cell Lines”, Oncogene, vol. 12, 1996, pp. 1005-1014.
Paul N. Baird, et al., “Expressions of the Wilms' Tumor Gene (WT1) in Normal Hemopoiesis”, Experimental Hematology, 25, 1997, pp. 312-320.
Christine E. Campbell, et al., “Constitutive Expression of the Wilms Tumor Suppressor Gene (WT1) in Renal Cell Carcinoma”, Int. J. Cancer, vol. 78, 1998, pp. 182-188.
Kazushi Inoue, et al., “WT1 as a New Prognostic Factor and a New Marker for the Detection of Minimal Residual Disease in Acute Leukemia”, Blood, vol. 84, No. 9, Nov. 1, 1994, pp. 3071-3079.
Kazushi Inoue, et al., “Aberrant Overexpression of the Wilms Tumor Gene (WT1) in Human Leukemia”, Blood, vol. 89, No. 4, Feb. 15, 1997, pp. 1405-1412.
Kazushi Inoue, et al., “Wilms' Tumor Gene (WT1) Competes with Differentiation-Inducing Signal in Hematopoietic Progenitor Cells”, Blood, vol. 91, No. 8, Apr. 15, 1998, pp. 2969-2976.
Ulrich Maurer, et al., “The Wilms' Tumor Gene is Expressed in a Subset of CD34+Progenitors and Downregulated Early in the Course of Differentiation in Vitro”, Experimental Hematology, vol. 25, 1997, pp. 945-950.
Tamotsu Yamagami, et al., “Growth Inhibition of the Human Leukemic Cells by WT1 (Wilms Tumor Gene) Antisense Oligodeoxynucleotides: Implications for the Involvement of WT1 in Leukemogenesis”, Blood, vol. 87, No. 7, Apr. 1, 1996, pp. 2878-2884.
Kazushi Inoue, et al., “Long-Term Follow-Up of Minimal Residual Disease in Leukemia Patients by Monitoring WT1 (Wilms Tumor Gene) Expression Levels”, Blood, vol. 88, No. 6, Sep. 15, 1996, pp. 2267-2278.
H. Ogawa, et al., “Successful Donor Leukocyte Transfusion at Molecular Relapse for a Patient with Acute Myeloid Leukemia Who was Treated with Allogeneic Bone Marrow Transplantation: Importance of the Monitoring of Minimal Residual Disease by WT1 Assay”, Bone Marrow Transplantation, vol. 21, 1998, pp. 525-527.
Hans D. Menssen, et al., “Detection by Monoclonal Antibodies of the Wilms' Tumor (WT1) Nuclear Protein in Patients with Acute Leukemia”. vol. 70, 1997, pp. 518-523.
HD Menssen, et al., “Presence of Wilms' Tumor Gene (wt1) Transcripts and the WT1 Nuclear Protein in the Majority of Human Acute Leukemias”, Leukemia, vol. 9, 1995, pp. 1060-1067.
Gary B. Silberstein, et al., “Altered Expression of the WT1 Wilms Tumor Suppressor Gene in Human Breast Cancer”, Proc. Natl. Acad. Sci. USA, vol. 94, Jul. 1997, pp. 8132-8137.
Alessandra Viel, et al., “Molecular Mechanisms Possibly Affecting WT1 Function in Human Ovarian Tumors”, Int. J. Cancer, vol. 57, 1994, pp. 515-521.
Jennifer F. Morris, et al., “Characterization of the Zinc Finger Protein Encoded by the WT1 Wilms' Tumor Locus”, Oncogene, vol. 6, 1991, pp. 2339-2348.
A.L. Menke, et al., “The Wilms' Tumor 1 Gene : Oncogene or Tumor Suppressor Gene?”, International Review of Cytology, vol. 181, 1998, pp. 151-212.
Mitsuhiko Osaka, et al., “WT1 Contributes to Leukemogenesis: Expression Patterns in 7, 12 -Dimethylbenz[a]Anthracene (DMBA)-Induced Leukemia”, Int. J. Cancer, vol. 72, 1997, pp. 696-699.
Ulrich Rodeck, et al., “Expression of the WT1 Wilms' Tumor Gene by Normal and Malignant Human Melanocytes”, Int. J. Cancer, vol. 59, 1994, pp. 78-82.
Helena Svedberg, et al., “Constitutive Expression of the Wilms' Tumor Gene (WT1) in the Leukemic Cell Line U937 Blocks Parts of the differentiation Program”, Oncogene, vol. 16, 1998, pp. 925-932.
Kentaro Semba, et al., “cDNA Cloning and its Pronephros-Specific Expression of the Wilms' Tumor Suppressor Gene, WT1, from Xenopus Laevis”, Gene, vol. 175, 1996, pp. 167-172.
Fahad Al-Obeidi, et al., “Peptide and Peptidomimetic Libraries, Molecular Diversity and Drug Design”, Molecular Biotechnology, vol. 9, Jun. 1998, pp. 205-223.
Elena Sadovnikova, et al., “Peptide-Specific Cytotoxic T Lymphocytes Restricted by Nonself Major Histocompatibility Complex Class I Molecules: Reagents for Tumor Immunotherapy”, Proc. Natl. Acad Sci., Immunology, vol. 93. Nov. 1996, pp. 13114-13118.
Joke M. M. Den Haan, et al., “The Minor Histocompatibility Antigen HA-1: A Diallelic Gene with a Single Amino Acid Polymorphism”, Science, vol. 279, Feb. 13, 1998, pp. 1054-1057.
Jeffrey J. Molldrem, et al., “Cytotoxic T Lymphocytes Specific for a Nonpolymorphic Proteinase 3 Peptide Preferentially Inhibit Chronic Myeloid Leukemia Colony-Forming Units”, Blood, vol. 90, No. 7, Oct. 1, 1997, pp. 2529-2534.
Elena Sadovnikova, et al., “Generation of Human Tumor Reactive Cytotoxic T Cells Against Peptides Presented by non-self HLA Class I Molecules”, Eur. J. Immunol., vol. 28, Jan. 1998, pp. 193-200.
Yutaka Kawakami, et al., “Identification of a Human Melano
Oka Yoshihiro
Sugiyama Haruo
Helms Larry R.
International Institute of Cancer Immunology, Inc.
Natarajan Meera
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
LandOfFree
Tumor antigen based on products of the tumor suppressor gene... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tumor antigen based on products of the tumor suppressor gene..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor antigen based on products of the tumor suppressor gene... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4227219